Welcome to our dedicated page for Arcadia Bioscien news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Bioscien stock.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) regularly issues news and updates as a producer and marketer of plant-based and innovative wellness products. With its roots in agricultural innovation and a current focus on Zola coconut water and related wellness offerings, the company’s announcements provide insight into its operating performance, strategic direction, and capital markets activity.
News items for RKDA often include quarterly and annual financial results, where Arcadia reports revenue trends, gross margin performance, and changes in operating expenses. These releases detail how Zola coconut water revenues and distribution have evolved over time, and how asset sales, credit losses, and fair value changes in financial instruments have affected net income or loss attributable to common stockholders.
Arcadia’s news flow also covers strategic transactions and corporate actions. Examples include the sale of its GoodWheat brand and wheat-related intellectual property, agreements to transfer or terminate certain patent rights, and the previously announced but later terminated proposed business combination with Roosevelt Resources, LP. Press releases describe the rationale for these actions and their role in streamlining operations and evaluating strategic alternatives.
Investors following RKDA news will also see capital-raising and securities-related announcements, such as inducement transactions involving preferred investment options and the issuance of new options and placement agent options, as disclosed in company filings and related press releases. In addition, Arcadia publishes notices about upcoming earnings releases, conference calls, and virtual stockholder meetings, along with proxy and governance information.
This news page aggregates these disclosures so readers can review Arcadia’s earnings reports, transaction updates, financing developments, and governance communications in one place. For those tracking RKDA, the feed offers a structured view of how the company describes its business focus, financial condition, and strategic plans over time.
Arcadia Biosciences (Nasdaq: RKDA) will release its third quarter and first nine months of 2022 financial results after market close on November 10, 2022. A conference call is scheduled for 4:30 p.m. Eastern time to discuss these results and key strategic achievements. Participants can join via U.S. toll-free at +1-866-374-5140 or internationally at +1-404-400-0571, using the passcode 14010760. This session will also be available via a live webcast on the company's investor website.
Arcadia Biosciences (Nasdaq: RKDA) announced its participation in two upcoming investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference, taking place from September 12-14 in New York City, where CEO Stan Jacot will present on September 13 at 5:00 p.m. ET. The second event is the Lake Street Capital Markets' 6th Annual Best Ideas Growth Conference on September 14, also in New York City. Investors can register for meetings through the respective conference websites.
Arcadia Biosciences (Nasdaq: RKDA) has completed a registered direct offering of 4,722,506 shares priced at $1.05876 per share, raising approximately $4.57 million in net proceeds. These funds will be utilized to support Project Greenfield, aimed at profitability through expanding retail for their GoodWheat high-fiber pasta and other core brands. Additionally, the company issued preferred investment options for the same number of shares with an exercise price of $0.93376, valid for five years.
Arcadia Biosciences (Nasdaq: RKDA) announced a registered direct offering of 4,722,506 shares of common stock at $1.05876 per share, totaling approximately $5 million in gross proceeds. The offering is part of a three-year initiative, Project Greenfield, aimed at expanding its GoodWheat brand and driving growth in core products. The offering, facilitated by H.C. Wainwright & Co., is set to close on or around August 16, 2022, pending usual conditions. The unregistered investment options for additional shares will also be made available, exercisable at $0.93376 per share.
Arcadia Biosciences (Nasdaq: RKDA) reported a 175% increase in revenue for Q2 2022, totaling $3.9 million, driven by successful launches of GoodWheat™ pasta and sales of Zola products. In the first half of 2022, total revenues reached $7.1 million, up from $2.2 million year-over-year. The company recognized a $2 million milestone for HB4® soybean approval in China. However, net losses narrowed to $3.8 million from $5.3 million in Q2 2021. Project Greenfield aims to drive profitability.
Arcadia Biosciences (Nasdaq: RKDA) announced that it will release its financial results for the second quarter and first half of 2022 after market close on August 11, 2022.
A conference call to discuss these results and key strategic achievements is scheduled for 4:30 p.m. Eastern time. Participants can join via U.S. toll-free dial-in at +1-866-374-5140 or international dial-in at +1-404-400-0571. A live webcast will also be available on the company’s website.
GoodWheat™ pasta, developed by Arcadia Biosciences (Nasdaq: RKDA), has launched as a healthier alternative in the pasta category, featuring one key ingredient. This innovative pasta boasts 4x the fiber (8g per serving) and 9g of protein, offering enhanced nutrition without compromising taste. Available in five varieties for $3.99 per 12-oz. package, GoodWheat pasta is Non-GMO Project Verified and kosher certified. The product aims to cater to consumers seeking healthier options while maintaining the traditional taste of pasta, marking a significant step for the company's expansion into better-for-you food products.
Arcadia Biosciences (RKDA) reported a remarkable 48% increase in sales from Q4 2021, reaching $3.2 million in Q1 2022, a 289% year-over-year growth. The company's transition to a consumer packaged goods (CPG) model and acquisitions of wellness brands contributed significantly to this growth. Moreover, Arcadia shipped its first retail orders of GoodWheat™ pasta and anticipates $2 million from the approval of HB4® soybeans in China. However, the company reported a net loss of $4.5 million, a shift from a profit of $2.1 million in Q1 2021.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) will release its Q1 2022 financial results on May 12, 2022, after market close. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern time on the same day, with dial-in numbers provided. The company specializes in plant-based health products and has a range of offerings including GoodWheat™ and Zola® coconut water. A live webcast of the call will be available on Arcadia's investor website, with a recorded replay following the event.
Arcadia Biosciences (Nasdaq: RKDA) announced its fourth quarter and full-year 2021 financial results, revealing a significant revenue decline of 70% in Q4 2021 to $2.2 million, compared to $7.1 million in Q4 2020. Annual revenue also fell by 16% to $6.78 million. Operating expenses surged to $15.975 million in Q4 and $42.306 million for the year, leading to a net loss of $9.282 million for Q4 and $14.660 million for 2021. The company focuses on expanding its GoodWheat portfolio and recently appointed CPG industry veteran Stan Jacot as CEO to enhance growth strategies.
FAQ
What is the current stock price of Arcadia Bioscien (RKDA)?
What is the market cap of Arcadia Bioscien (RKDA)?
